Neumora Therapeutics Q3 net loss narrows 39% to $34.44 million
NMRA•
NMRA•Neumora Therapeutics’ third-quarter 2026 net loss narrowed 39% year over year to $34.44 million. Cash and cash equivalents totaled $85.65 million at September 30, and the company submitted an investigational new drug application for NMRA-215.
Neumora Therapeutics’ third-quarter 2026 net loss narrowed 39% year over year to $34.44 million. Research and development expenses fell 44% to $22.61 million, reflecting lower clinical trial and personnel-related costs. Cash and cash equivalents totaled $85.65 million at September 30, and management is evaluating funding options for its lead programs.
The company submitted an FDA investigational new drug application for NMRA-215, an oral NLRP3 inhibitor targeting obesity and cardiometabolic disease. NMRA-511 demonstrated favorable safety and dose-proportional exposure at 30 mg twice daily, and the program is Phase 2 enabled.